NEW YORK (GenomeWeb News) – A substantial investor in Illumina's stock is suing the company alleging breach of fiduciary duty in connection with Roche's efforts to buy the San Diego-based company and its efforts to fend off that approach.

In a lawsuit filed with the US District Court, Southern District of New York this week, the plaintiffs, Vista Capital Management, seeks damages of more than $10 million.

Based in Geneva, Vista is a privately held financial services firm that owned more than 300,000 shares of Illumina stock during the periods covered by its lawsuit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.